Synthesis and biological evaluation of five-membered heterocycles fused to cyclopenta[c]thiophene as new antitumor agents

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 7, 2003, Pages 1161-1167

  Dallemagne, Patrick ^a   Khanh, Lan Pham ^a   Alsaïdi, Abdellah ^a   Varlet, Isabelle ^a   Collot, Valérie ^a   Paillet, Magalie ^a   Bureau, Ronan ^a   Rault, Sylvain ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIBROMO 5,6 DIHYDROXY 5,6 DIHYDRO 4H CYCLOPENTA[C]THIOPHEN 4 ONE; 1,3,5 TRIBROMO 4 OXO 5,6 DIHYDRO 4H CYCLOPENTA[C]THIEN 6 YLAMMONIUM CHLORIDE; 4 BROMO 3A,7A DIHYDRO 2H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOLE 2,7(3H) DIONE; 4 BROMO 6 (3,4 DIMETHOXYPHENYL) 3A,7A DIHYDRO 2H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOLE 2,7(3H) DIONE; 4 BROMO 6 PYRROLIDIN 1 YL 3A,7A DIHYDRO 2H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOLE 2,7(3H) DIONE; 4,6 DIBROMO 2 THIOXO 2,3,3A,7A TETRAHYDRO 7H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOL 7 ONE; 4,6 DIBROMO 2 THIOXO 2,3,3A,7A TETRAHYDRO 7H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]THIAZOL 7 ONE; 4,6 DIBROMO 3A,7A DIHYDRO 2H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOLE 2,7(3H) DIONE; 4,6 DIBROMO 3AH THIENO[3',4':3,4]CYCLOPENTA[1,2 D][1,3]DIOXOLE 2,7(7AH) DIONE; 4,6 DICHLORO 3A,7A DIHYDRO 2H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOLE 2,7(3H) DIONE; 4,6 DIIODO 3A,7A DIHYDRO 2H THIENO[3',4':4,5]CYCLOPENTA[1,2 D][1,3]OXAZOLE 2,7(3H) DIONE; ANTINEOPLASTIC AGENT; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; HISTOLOGY; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; XENOGRAFT;

EID: 0037375655     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00654-5     Document Type: Article

References (10)

1. Dallemagne P., Pham Khanh L., Alsaïdi A., Renault O., Varlet I., Collot V., Bureau R., Rault S. Bioorg. Med. Chem. 10:2002;2185.
2. Hollingshead M.G., Alley M.C., Camalier R.F., Abbott B.J., Mayo J.G., Malspeis L., Grever M.R. Life Sci. 57:1995;131.
3. Pham Khanh L., Dallemagne P., Rault S. Synthesis. 8:2002;1091.
4. Alsaïdi A., Al Shargapi S., Dallemagne P., Carreiras F., Gauduchon P., Rault S., Robba M. Chem. Pharm. Bull. 42:1994;1605.
5. Dallemagne P., Alsaïdi A., Boulouard M., Rault S., Robba M. Heterocycles. 36:1993;287.
6. Ruhland B., Bombrun A., Gallop M.A. J. Org. Chem. 62:1997;7820.
7. Dallemagne P., Pilo J.C., Rault S., Robba M., Saux M., Carpy A. Heterocycles. 34:1992;1317.
8. Boyd M.R., Paull K.D. Drug Dev. Res. 34:1995;91.
9. Argade A.B., Devraj R., Vroman J.A., Haugwitz R.D., Hollingshead M., Cushman M. J. Med. Chem. 41:1998;3337.
10. Paull K.D., Shoemaker R.H., Hodes L., Monks A.P., Scudiero D.A., Rubinstein L.V., Plowman J., Boyd M.R. J. Natl. Cancer Inst. 81:1989;1088.